Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
…, D Fergusson, M Halpenny, L Hamelin, L Huebsch… - The Lancet, 2016 - thelancet.com
Background Strong immunosuppression, including chemotherapy and immune-depleting
antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been …
antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been …
Guidelines on the use of intravenous immune globulin for hematologic conditions
…, S Couban, P Radmoor, L Huebsch… - Transfusion medicine …, 2007 - Elsevier
Canada's per capita use of intravenous immune globulin (IVIG) grew by approximately 115%
between 1998 and 2006, making Canada one of the world's highest per capita users of IVIG…
between 1998 and 2006, making Canada one of the world's highest per capita users of IVIG…
[HTML][HTML] Continuous multi-parameter heart rate variability analysis heralds onset of sepsis in adults
S Ahmad, T Ramsay, L Huebsch, S Flanagan… - PloS one, 2009 - journals.plos.org
Background Early diagnosis of sepsis enables timely resuscitation and antibiotics and
prevents subsequent morbidity and mortality. Clinical approaches relying on point-in-time …
prevents subsequent morbidity and mortality. Clinical approaches relying on point-in-time …
[HTML][HTML] Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem …
Hepatic veno-occlusive disease (HVOD) is a serious life-threatening complication of
hematopoietic stem cell transplantation (HSCT). Currently, there is no optimal therapeutic strategy …
hematopoietic stem cell transplantation (HSCT). Currently, there is no optimal therapeutic strategy …
Myasthenia gravis treated with autologous hematopoietic stem cell transplantation
…, L Hamelin, M Hodgins, H Hopkins, L Huebsch… - JAMA …, 2016 - jamanetwork.com
Importance Some patients with myasthenia gravis (MG) do not respond to conventional
treatment and have severe or life-threatening symptoms. Alternate and emerging therapies have …
treatment and have severe or life-threatening symptoms. Alternate and emerging therapies have …
Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13‐year followup
RJR McKendry, L Huebsch… - Arthritis & Rheumatism …, 1996 - Wiley Online Library
The progression of rheumatoid arthritis (RA) is documented in a patient receiving a sex‐mismatched,
allogeneic bone marrow transplant (BMT) for gold‐induced marrow aplasia. DNA …
allogeneic bone marrow transplant (BMT) for gold‐induced marrow aplasia. DNA …
[HTML][HTML] Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study
… Lothar Huebsch assisted with data analysis and manuscript preparation. Dean Fergusson
assisted with data analysis and interpretation, and manuscript preparation. Marc Carrier and …
assisted with data analysis and interpretation, and manuscript preparation. Marc Carrier and …
[HTML][HTML] An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting
…, C Leger, S Couban, D Simpson, L Huebsch… - Biology of Blood and …, 2004 - Elsevier
We compared the donation of bone marrow (BM) versus recombinant human granulocyte
colony-stimulating factor-mobilized peripheral blood progenitor cells (PBPC) in HLA-matched …
colony-stimulating factor-mobilized peripheral blood progenitor cells (PBPC) in HLA-matched …
[HTML][HTML] Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple …
…, T Iqbal, MA Zaidi, SA McDiarmid, LB Huebsch… - Biology of Blood and …, 2008 - Elsevier
Patients with coexisting medical problems may suffer increased toxicity and reduced quality
of life after autologous hematopoietic stem cell transplantation (HSCT). The benefit of high-…
of life after autologous hematopoietic stem cell transplantation (HSCT). The benefit of high-…
[HTML][HTML] Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
…, M Tokessy, R Mallick, S McDiarmid, L Huebsch… - Biology of Blood and …, 2013 - Elsevier
Hematopoietic stem cell transplantation (HSCT) recipients are a high-risk, immunocompromised
group of patients who receive frequent transfusions after transplantation. Transfusion of …
group of patients who receive frequent transfusions after transplantation. Transfusion of …